…

As flu season looms with last year's record severity, Genentech steps up with a game-changing move: selling Xofluza directly to patients for just $50. But can this discounted antiviral really reach those left behind by high costs, or is it just the start of bigger battles over drug prices?

Bank of America believes this newly public data center company could double in value. With record bookings and analysts lining up with buy ratings, is Csquare the next big winner in the AI infrastructure race? The details might surprise you...

Bitcoin just posted its strongest two-day gain in months after a high-stakes White House meeting and a massive short squeeze. The Clarity Act suddenly looks alive again, but one September vote could still kill the momentum. Here's the full picture.